Fed Circ injects new life into Mylan dispute

Appeals court faults lower court’s claim construction and its reliance on intrinsic evidence alone | Court emphasises that extrinsic evidence is needed in litigation over heart disease drug.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

EU: Finland liability regime 'compatible' in big pharma feud

11 January 2024 Case concerns a supplementary protection certificate granted to Gilead by Finland’s Patent Office for a HIV drug |CJEU judges contradict AG opinion on whether a Finnish regime is at odds with an EU directive.

Americas

AstraZeneca says Mylan, Kindeva infringe another Symbicort patent

28 April 2022 AstraZeneca filed a patent infringement lawsuit against Mylan Pharmaceuticals and Kindeva Drug Delivery on Tuesday, claiming that their generic asthma Symbicort infringes a brand-new patent that was issued the same day.

Americas

Mylan, Edwards back NHK-Fintiv challenge

31 August 2021 Mylan Pharmaceutical and Edwards Lifesciences have joined a petition urging the US Supreme Court to order the US Court of Appeals for the Federal Circuit to reconsider inter partes review petitions that have been denied due to the NHK-Fintiv rule.